2seventy bio is proud to announce a significant milestone in our journey to transform cancer treatment—we have successfully raised $286,000,000 in our latest funding round. As an innovative immuno-oncology cell therapy company, our mission is to discover and develop next-generation therapies that truly disrupt the cancer treatment landscape. Our company name, 2seventy bio, is inspired by the notion of converting human thought into action at a breathtaking pace of 270 miles per hour, reflecting our relentless drive to think and act in real time. With our deep expertise in cancer cell metabolism, genomics, and the intricate dance between tumor cells and the human immune system, we are uniquely positioned to pioneer cellular therapies that “think” smarter and faster than cancer itself.
This infusion of capital will fuel our ambitious research and development initiatives, accelerate clinical studies, and expand our capacity to explore novel immuno-oncology strategies. We are committed to harnessing cutting-edge science and technology to deliver breakthroughs that translate into life-changing therapies for people living with cancer. Each day, minute, and second counts, and with this funding we are more empowered than ever to expedite the transition from laboratory insights to innovative treatments in the clinic. Supported by visionary investors who share our passion for innovation and our unwavering commitment to patients, 2seventy bio is set to embark on the next phase of growth. Our team is excited to leverage this investment to not only drive scientific discovery but also to redefine the standards of cancer care—ultimately ensuring that every moment matters in the fight against this devastating disease.
